Nuvilex Inc. (NASDAQ:PMCB – Get Free Report)’s share price shot up 0.2% during trading on Friday . The stock traded as high as $0.5712 and last traded at $0.5510. Approximately 131,483 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 131,438 shares. The stock had previously closed at $0.55.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded Nuvilex from a “sell (d)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Read Our Latest Stock Report on PMCB
Nuvilex Stock Up 0.2%
About Nuvilex
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.
Further Reading
- Five stocks we like better than Nuvilex
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
